{"id":3111,"date":"2018-06-04T11:46:32","date_gmt":"2018-06-04T11:46:32","guid":{"rendered":"http:\/\/impulse-dynamics-multisite.flywheelsites.com\/ous\/int\/?post_type=news&p=3111"},"modified":"2018-06-04T11:46:32","modified_gmt":"2018-06-04T11:46:32","slug":"clinical-registry-data-recently-published-fix-hf-5c-presented-late-breaking-clinical-trial-session-ehf-2018","status":"publish","type":"news","link":"https:\/\/impulse-dynamics.com\/global\/news\/clinical-registry-data-recently-published-fix-hf-5c-presented-late-breaking-clinical-trial-session-ehf-2018\/","title":{"rendered":"Clinical Registry Data and recently published FIX-HF-5C were presented at the Late-Breaking Clinical Trial Session at EHF 2018"},"content":{"rendered":"

Stuttgart, Germany, May 28th, 2018 \u2013 Impulse Dynamics Germany, GmbH announced results on \u201cReal World\u201d experience from its European Clinical Registry. The results were presented today by Prof. Gerd Hasenfu\u00df, MD, Professor of Internal Medicine and Director of the Heart Center, University Hospital G\u00f6ttingen, Germany at the Late-Breaking Clinical Trials Session of the European Heart Failure Congress in Vienna, Austria.<\/p>\n

\"\"

Prof. G. Hasenfu\u00df, M.D. Director of the Heart Center, University Hospital G\u00f6ttingen, Germany<\/p><\/div>\n

CCM\u2122 is a therapy unique to the Optimizer\u00ae family of devices that deliver electrical signals to the heart that are intended to reduce symptoms and improve exercise tolerance in patients with heart failure (HF). 140 of the patients enrolled in the observational registry in Europe had characteristics similar to those of the patients enrolled in the recently finished US FIX-HF-5C study: QRS <130 msec, ejection fraction (EF) between 25% and 45% and NYHA class III or IV HF. Enrollment occurred based on clinical need and all data was independently monitored. The patients in the registry were followed for up to 2 years for hospitalizations, Minnesota Living with Heart Failure Questionnaire (MLWHFQ), and NYHA, and followed up to 3 years for mortality. Reported mortality was compared with that predicted by the Seattle Heart Failure Model (SHFM) and the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC). A separate analysis was performed on the subgroup of patients with EF between 25-34% and 35-45%.<\/p>\n

Highlights of the CCM-Registry results include:<\/p>\n